Abstract
Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.
Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors
Current Enzyme Inhibition
Title: Cholinesterases and Cholinesterase Inhibitors
Volume: 4 Issue: 4
Author(s): Sarka Stepankova and Karel Komers
Affiliation:
Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors
Abstract: Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.
Export Options
About this article
Cite this article as:
Stepankova Sarka and Komers Karel, Cholinesterases and Cholinesterase Inhibitors, Current Enzyme Inhibition 2008; 4 (4) . https://dx.doi.org/10.2174/157340808786733631
DOI https://dx.doi.org/10.2174/157340808786733631 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuronal and Glial Responses to Polyamines in the Ischemic Brain
Current Neurovascular Research Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders
Current Medicinal Chemistry RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry 6-Acetyl-5H-thiazolo[3,2-a]pyrimidine Derivatives as the Novel Acetylcholinesterase Inhibitors: Design, Synthesis, and Biological Activity
Medicinal Chemistry Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Mechanisms of Acupuncture Effect on Alzheimer’s Disease in Animal- Based Researches
Current Topics in Medicinal Chemistry Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) Statistical Voxel-Based Methods and [18F]FDG PET Brain Imaging: Frontiers for the Diagnosis of AD
Current Alzheimer Research Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future Directions
Current Pharmaceutical Design Oral Health in Alzheimers Disease: A Review
Current Alzheimer Research Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology Histone Deacetylation and Motor Neuron Degeneration
CNS & Neurological Disorders - Drug Targets Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry A MicroRNA-BDNF Negative Feedback Signaling Loop in Brain: Implications for Alzheimer’s Disease
MicroRNA Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy